What is Traws Pharma?
Traws Pharma is dedicated to pioneering oral small molecule therapies for challenging conditions such as respiratory viral diseases and various forms of cancer. Its viral respiratory disease program features ratutrelvir, an oral inhibitor of the SARS-CoV-2 Mpro, and tivoxavir marboxil, an investigational oral antiviral for influenza targeting the influenza cap-dependent endonuclease. In its oncology efforts, Traws is advancing narazaciclib, a proprietary multi-kinase CDK4-plus inhibitor, with potential applications in refractory endometrial cancer and other solid tumors, designed to overcome resistance pathways associated with CDK inhibitors. The company leverages state-of-the-art drug development technology, prioritizing patient safety and aiming to alleviate the global burden of viral infections and cancer.
How much funding has Traws Pharma raised?
Traws Pharma has raised a total of $72.6M across 1 funding round:
Other Financing Round
$72.6M
Other Financing Round (2024): $72.6M with participation from Tungsten Advisors
Key Investors in Traws Pharma
Tungsten Advisors
Tungsten Advisors is an investment banking firm specializing in strategic advisory and corporate finance for healthcare and technology sectors. They provide transactional services including financings, corporate licensing, and M&A, and also engage in company incubation and direct investments.
What's next for Traws Pharma?
With the infusion of $72.6M in this major strategic investment, Traws Pharma is expected to significantly advance its clinical programs. The capital will likely fuel the progression of its lead candidates, ratutrelvir and narazaciclib, through further clinical trials and regulatory processes. This funding round, contextualized as enterprise-level, suggests Traws Pharma is entering a crucial scaling phase, potentially expanding its research and development capabilities and preparing for commercialization. The company's focus on both viral diseases and oncology indicates a diversified strategy to address significant healthcare challenges, making its next steps closely watched within the biopharmaceutical sector.
See full Traws Pharma company page
